Letrozole or Anastrozole

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, The Affiliated Hospital of Qingdao University

Conditions

Breast CancerBreast DiseasesNeoplasms

Phase 2

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

CompletedNCT03839823

Novartis PharmaceuticalsBreast Cancer

Start: 2019-02-25End: 2023-05-10Updated: 2024-10-09

Unknown Phase

A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer

Not yet recruitingNCT06341283

The Affiliated Hospital of Qingdao UniversityBreast Cancer, Breast Diseases, Neoplasms

Start: 2024-06-01End: 2025-07-01Target: 200Updated: 2024-05-10

Related Papers

First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.

Journal of Clinical Oncology2025-05-28

Opinions of real-world clinicians regarding visceral crisis in HR+/HER2- mBC: Results from the RETRACT survey of US oncologists.

Journal of Clinical Oncology2025-05-28

Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.

Journal of Clinical Oncology2023-06-0110 citations

Abstract GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy

Cancer Research2023-03-0141 citations